ACT-293987 in Pulmonary Arterial Hypertension

This study is ongoing, but not recruiting participants.

Sponsor:

Information provided by (Responsible Party):

Actelion

ClinicalTrials.gov Identifier:

NCT01112306

First received: April 8, 2010

Last updated: August 29, 2017

Last verified: August 2017

History of Changes

Purpose

Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)

Condition	Intervention	Phase
Pulmonary Arterial Hypertension	Drug: ACT-293987	Phase 3


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
Official Title:	Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension

Resource links provided by NLM:

Genetics Home Reference related topics: pulmonary arterial hypertension

Drug Information available for: Selexipag

Genetic and Rare Diseases Information Center resources: Pulmonary Arterial Hypertension

U.S. FDA Resources

Further study details as provided by Actelion:

Primary Outcome Measures:

Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Up to end of study. The duration of the study will be country-dependent and based on the results of the AC-065A302 study. ]


Estimated Enrollment:	670
Study Start Date:	December 1, 2009
Estimated Study Completion Date:	February 1, 2021
Estimated Primary Completion Date:	February 1, 2021 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 ACT-293987, twice daily	Drug: ACT-293987 Tablets, twice daily

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients who participated to the double-blind study AC-065A302 and either had a morbidity event or had completed the study as scheduled per protocol.
Signed informed consent.

Exclusion Criteria:

Patients who have started receiving prostacyclin (epoprostenol) or prostacyclin analogs (i.e., treprostinil, iloprost, beraprost) since the last study drug intake in AC-065A302/GRIPHON.
Severe hepatic impairment (Child-Pugh C).
Females who are pregnant or who plan to become pregnant during the study, or are breastfeeding.
Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence, or psychiatric disease.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01112306

Show 156 Study Locations

Sponsors and Collaborators

Actelion

Investigators


Study Director:	Aline Frey	Actelion

More Information


Responsible Party:	Actelion
ClinicalTrials.gov Identifier:	NCT01112306 History of Changes
Other Study ID Numbers:	AC-065A303
Study First Received:	April 8, 2010
Last Updated:	August 29, 2017

Keywords provided by Actelion:


Open-label PAH Pulmonary Arterial Hypertension

Additional relevant MeSH terms:


Hypertension Familial Primary Pulmonary Hypertension Vascular Diseases Cardiovascular Diseases Hypertension, Pulmonary	Lung Diseases Respiratory Tract Diseases Selexipag Antihypertensive Agents

ClinicalTrials.gov processed this record on September 21, 2017

To Top